Skip to main content

A Taxing Consequence: Taxane Acute Pain Syndrome

JHOP - June 2017 Vol 7, No 2 - Supportive Care, Symptom Management Overview
Mark L. Zangardi, PharmD, BCOP
Clinical Pharmacist
Ambulatory Oncology
Massachusetts General Hospital
Boston, MA
Download PDF

This section provides a quick update of symptomatic conditions in oncology and their management. Readers are invited to submit brief updates following the guidelines at

Symptom Overview

The taxanes (eg, docetaxel and paclitaxel) are important components of chemotherapeutic regimens for a variety of cancers, including breast, genitourinary, gynecologic, and lung malignancies. Taxanes are among the most frequently used chemotherapeutic agents for curative and palliative intent. Toxicities often attributed to the taxanes include myelosuppression, hyper­sensitivity, fatigue, gastrointestinal disturbances (ie, nausea, vomiting, or diarrhea), alopecia and other dermatologic toxicities, and peripheral neuropathy or neuropathic pain.1,2

Acute pain associated with taxane therapy is referred to as taxane acute pain syndrome (TAPS), paclitaxel-associated acute pain syndrome, or taxane-induced myalgia–arthralgia syndrome; it is a distinct entity from the well-described neurotoxicity associated with taxanes.3-5 TAPS is generally characterized as diffuse, achy myalgias and/or arthralgias that present within 24 to 48 hours of taxane administration, and may last for up to 7 days.3-8 There are no clear definitions or standard tools for assessing TAPS, which results in a wide variation of its incidence in the published literature.

TAPS has been described in up to 86% of patients according to 1 systematic review, and it may be more common with paclitaxel than with docetaxel or with nab-paclitaxel.5 In this systematic review, the incidence of TAPS varied between taxanes; paclitaxel, median, 13.1% (range, 0.9%-86%); docetaxel, median, 10.5% (range, 3.6%-70%); and nab-paclitaxel, median, 26% (range, 14%-43%).

The dosing schedule may also affect the incidence of TAPS with the use of paclitaxel, with every-3-weeks administration resulting in higher rates of TAPS compared with weekly dosing (median incidence, 52.7% vs 17.6%, respectively).5

The risk factors are not well-established, but some reports have associated TAPS with increased single doses, higher peak drug levels, greater body surface area, concomitant medications (eg, granulocyte colony-stimulating factors), treatment for breast cancer, and treatment in the metastatic setting.3-5,8,9

TAPS may be debilitating in a subset of patients, affecting quality of life and requiring therapy modification (eg, chemotherapy dose interruptions, reductions, or discontinuation).4,7 Modifying the dosing schedule (eg, switching from every 3 weeks to weekly paclitaxel) or changing to a drug associated with less myalgia or arthralgia may also be considered if alternative effective chemotherapy drugs are available for the specific cancer type. In addition, pharmacologic intervention may be required.4,7

A single-center, retrospective pilot study showed that 43% of patients who received a sequential anthracycline-based and taxane-based chemotherapy regimen for early-stage breast cancer had pain requiring management with narcotics.10



The etiology of TAPS has not been fully elucidated, but proposed mechanisms include inflammation,11 peripheral nerve toxicity (direct or secondary as a result of inflammation) with nociceptor sensitization and resultant hyperalgesia,3,4,6 and immune system activation.3 TAPS differs from taxane-induced neuropathic pain in several ways, including being an acute toxicity, noncumulative, and generally being transient and short-lived.3-5 However, some reports have identified that TAPS may precede and predispose peripheral neuropathy.4,5


Treatment Options

A variety of pharmacologic agents have been reported as potential options for the treatment or secondary prevention of TAPS, including nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, antihistamines, tricyclic antidepressants, antiepileptics (ie, gabapentin and pregabalin), glutamine, and Shakuyaku-kanzo-to (Japanese herb).3-12 The majority of published reports are retrospective, case reports, or case series; the only published study that was placebo-controlled and double-blinded investigated glutamine for the prevention of TAPS, showing no benefit compared with placebo.12

Selected interventions, with specific drugs, drug classes, and dosing, for TAPS are highlighted in the Table. Given the paucity of data, variation in reporting, inconclusive results, and lack of prospective studies, the effective management of TAPS remains unclear, and no standard treatment is currently available.

Table 1

At the Massachusetts General Hospital Center for Breast Cancer, in Boston, patients beginning taxane-based chemotherapy are counseled about the potential for TAPS. Patients are instructed to report any myalgias or arthralgias after taxane administration. We encourage patients to use an NSAID (eg, ibuprofen 400-800 mg orally every 6-8 hours, as needed for pain) in the absence of contraindications. In cases of inadequate response to an NSAID therapy, the short-term use of an opioid, such as oxycodone, is considered as an adjunct to the NSAID.

Secondary prevention of TAPS with a corticosteroid (eg, dexamethasone 4 mg daily for 3-5 days) is considered for subsequent treatments with taxane-based chemotherapy, depending on the patient’s comorbidities. In addition, the use of a nonsedating antihistamine (eg, loratadine 10 mg daily for 3-5 days) may be of benefit in the secondary prevention of TAPS. Loratadine is an attractive option, because it is generally well-tolerated and can avoid the toxicities associated with NSAIDs (eg, gastrointestinal distress, renal damage, bleeding) and corticosteroids (eg, gastrointestinal distress, hypertension, hyperglycemia, irritability).

The Figure outlines strategies frequently used for the treatment and secondary prevention of TAPS at the Massachusetts General Hospital Center for Breast Cancer.

Figure 1



TAPS is a common early toxicity associated with taxane-based chemotherapy. It may affect the patient’s quality of life, resulting in chemotherapy treatment modification and/or the need for pharmacologic interventions. Currently no “gold standard” treatment is available for TAPS; however, symptomatic treatment with NSAIDs, opioids, and corticosteroids are common interventions. The use of antiepileptics, such as gabapentin or pregabalin, is an intriguing treatment option, because TAPS may be related to sensory nerve toxicity. Effective management of TAPS is paramount for optimizing the oncologic treatment of patients who receive taxanes, particularly in light of the suggested association between TAPS and the subsequent event of taxane-induced peripheral neuropathy. Further studies are needed to identify optimal assessment and treatment strategies for TAPS.

Author Disclosure Statement
Dr Zangardi has no conflicts of interest to report.


1. Taxol (paclitaxel) injection [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; April 2011.
2. Taxotere (docetaxel) injection [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US; December 2015.
3. Loprinzi CL, Reeves BN, Dakhil SR, et al. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol. 2011;29:1472-1478.
4. Seguin C, Kovacevich N, Voutsadakis IA. Docetaxel-associated myalgia-arthralgia syndrome in patients with breast cancer. Breast Cancer (Dove Med Press). 2017;9:39-44.
5. Fernandes R, Mazzarello S, Hutton B, et al. Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer—a systematic review. Support Care Cancer. 2016;24:3633-3650.
6. Loprinzi CL, Maddocks-Christianson KM, Wolf SL, et al. The paclitaxel acute pain syndrome: sensitization of nociceptors as the putative mechanism. Cancer J. 2007;13:399-403.
7. Nguyen VH, Lawrence JH. Use of gabapentin in the prevention of taxane-induced arthralgias and myalgias. J Clin Oncol. 2004;22:1767-1769.
8. Garrison JA, McCune JS, Livingston RB, et al. Myalgias and arthralgias associated with paclitaxel. Oncology (Williston Park). 2003;17:271-277.
9. Chiu N, Chiu L, Chow R, et al. Taxane-induced arthralgia and myalgia: a literature review. J Oncol Pharm Pract. 2017;23:56-67.
10. Saibil S, Fitzgerald B, Freedman OC, et al. Incidence of taxane-induced pain and distress in patients receiving chemotherapy for early-stage breast cancer: a retrospective, outcomes-based survey. Curr Oncol. 2010;17:42-47.
11. Markman M, Kennedy A, Webster K, et al. Use of low-dose oral prednisone to prevent paclitaxel-induced arthralgias and myalgias. Gynecol Oncol. 1999;72:100-101.
12. Jacobson SD, Loprinzi CL, Sloan JA, et al. Glutamine does not prevent paclitaxel-associated myalgias and arthralgias. J Support Oncol. 2003;1:274-278.

Related Items
Managing Differentiation Syndrome Associated with Treatment for AML
JHOP - February 2024 Vol 14, No 1 published on February 26, 2024 in Symptom Management Overview
Management of Iron Infusion Reactions
JHOP - December 2023 Vol 13, No 6 published on January 1, 2024 in Symptom Management Overview
Vancomycin Infusion Reaction: A Clinical and Therapeutic Overview
JHOP - June 2022 Vol 12, No 3 published on June 16, 2022 in Symptom Management Overview, Infusion Issues, Adverse Events
Ibrutinib-Related Atrial Fibrillation: An Anticoagulant Challenge
Zain Al-Jammali, PharmD, Brent Beckner, PharmD, Joseph Bubalo, PharmD, BCPS, BCOP
JHOP - June 2019 Vol 9, No 2 published on April 28, 2022 in Symptom Management Overview
HOP(A) Springs Eternal
Bryna Delman Ewachiw, PharmD, BCOP, Mark L. Zangardi, PharmD, BCOP
JHOP - March 2022 Vol 12 Special Feature published on March 22, 2022 in Editorial, HOPA Abstracts
Management of Acyclovir-Resistant Herpes Simplex Virus Infection in Patients Undergoing Hematopoietic Stem-Cell Transplantation
Jiyeon Joy Park, PharmD, BCOP, Esther Huang, PharmD, BCPS, BCOP, Colleen Ciccosanti, DO, MPH
JHOP - August 2021 Vol 11, No 4 published on August 17, 2021 in Symptom Management Overview, Transplant, Drug Resistance, Adverse Events
Denosumab for First-Line Treatment of Hypercalcemia Associated with Malignancy: Retrospective Analysis
Katherine P. Morgan, PharmD, BCOP, CPP, Yujiao Sun, PharmD, Allison Deal, Jared Weiss, MD, Amber Cipriani, PharmD, BCOP
JHOP - June 2021 Vol 11, No 3 published on June 16, 2021 in Original Article, Supportive Care, Immunotherapy, Adverse Events
How I Treat Anemia Associated with Lower-Risk Myelodysplastic Syndromes
Brenna Rowen, PharmD, BCOP
JHOP - June 2021 Vol 11, No 3 published on June 16, 2021 in Symptom Management Overview, Myelodysplastic Syndromes
Direct Oral Anticoagulant Therapy for Heparin-Induced Thrombocytopenia—A New Alternative?
Zain Al-Jammali, PharmD, Harleen Singh, PharmD, BCACP, Joseph Bubalo, PharmD, BCPS, BCOP, Joseph Shatzel, MD
JHOP - June 2020 Vol 10, No 3 published on June 22, 2020 in Symptom Management Overview, Oral Therapy
Prevention of Chemotherapy-Induced Nausea and Vomiting in Adult Patients Undergoing Hematopoietic Stem-Cell Transplant: Is Olanzapine an Option?
Ariel Denson, PharmD, Alyshia Wiggins, PharmD, Allison Martin, PharmD, BCOP, Justin Arnall, PharmD, BCOP, CPP
JHOP - April 2020 Vol 10, No 2 published on April 9, 2020 in Symptom Management Overview, CINV, Transplant